Empirico
Andrew Cicchetto is a Scientist at Empirico Inc., with experience in non-viral gene therapy platform development and immunosuppressive RNA therapeutic lipid nanoparticle payloads. Prior to this, Andrew was a research scientist at Poseida Therapeutics, Inc. where Andrew explored DNA format variations and engineered mutant proteins. Andrew completed their PhD in Molecular and Medical Pharmacology at UCLA, focusing on post-transcriptional regulation of metabolic genes. Andrew has also worked in various research roles at the University of California, Davis and Stem Cell Partners LLC. Their educational background includes a Master of Arts in Stem Cell Research and a Bachelor of Science in Biomedical Sciences from California State University-Sacramento.
This person is not in any teams
Empirico
1 followers
Empirico is a biotechnology company focused on the discovery and development of novel medicines which are designed to mimic naturally-occurring genetic variants that confer beneficial effects on health and disease. Empirico’s two foundational and proprietary technology platforms - the Precision Insights Platform™ for genetically-validated target discovery and siRCH™ for the discovery and development of siRNA medicines - are used separately and in tandem to enable Empirico and our collaborators from the discovery and validation of novel targets to the development of clinically-viable therapeutics. Empirico’s exceptional internal capabilities, augmented by those of its partners, are driving the advancement of a growing and differentiated pipeline of wholly-owned and partnered programs. Empirico is headquartered in San Diego, CA with a major second site in Madison, WI.